bis
Market Research Report

A quick peek into the report

Asia-Pacific Molecular Oncology Diagnostics Market

Focus on Cancer Type, End User, and Country - Analysis and Forecast, 2024-2033

 
Some Faq's

Frequently Asked Questions

The Asia-Pacific molecular oncology diagnostics market was valued at $513.6 million in 2024, and the market is expected to grow with a CAGR of 12.99% and reach $1,542.0 million by 2033.

Rising cancer incidence across China, India, Japan and SEA drives demand. Advancements in NGS, digital PCR and liquid biopsy enhance early, precise detection. Government genomics initiatives and public-private partnerships expand infrastructure. Increased funding in biotech R\&D, AI-driven bioinformatics, evolving reimbursement guidelines and clinical adoption further catalyze regional market growth.

Japan’s PMDA operates dedicated companion diagnostic approvals linked to drug authorizations. Australia’s TGA applies its IVD framework with mandatory clinical evaluation. China’s NMPA updated IVD guidelines mandate CDx device–drug co-approval. India’s CDSCO treats CDx as general IVDs without a distinct pathway. Other APAC nations follow a fragmented, often regionally harmonized ASEAN IVD framework.

The companies manufacturing molecular oncology diagnostics, service providers, pharmaceutical companies, and research institutions, among others should buy this report.

• Exhaustive product portfolio, recent developments, and company share of key players in the APAC molecular oncology diagnostics market

Similar Product

You may also like

Molecular Oncology Diagnostics Market - A Global and Regional Analysis
Published Year: 2025

Molecular Oncology Diagnostics Market - A Global and Regional Analysis: Focus on Product, Technology

The global molecular oncology diagnostics market was valued at $2,410.9 million in 2024, and...